EUSA Pharma Aims To Grow Through Acquisitions In Specialty Rx Market
This article was originally published in The Pink Sheet Daily
Executive Summary
EUSA Pharma announced the launch of operations March 23 with a group of products acquired from Jazz Pharmaceuticals and funding from equity investor Essex Woodlands; it is the third specialty pharma company set up by U.K. entrepreneur Bryan Morton.
You may also be interested in...
Izana Bioscience Set Up For Ankylosing Spondylitis Breakthrough
A new UK company set up by entrepreneur Bryan Morton to develop an innovative medicine for ankylosing spondylitis may be an example of how start-up companies could be supported through the UK's just announced industrial strategy for the life sciences sector.
Jazz Enters Oncology Market With EUSA Acquisition
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.
EUSA Pharma Gains Foothold In U.S. Market With Cytogen Acquisition
Buyout positions U.K. drug maker to take on new licensing deals on both sides of the Atlantic; oncology filing planned within 12 months, EUSA tells the DAILY.